Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 7,828 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Virus Infection, RNA Clear all
Completed Phase 3 Interventional Results available

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

NCT01492426
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Sargramostim in Patients With COVID-19

NCT04411680
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Sargramostim, Standard of care
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fullerton, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

NCT01687270
View directory record Official record
Conditions
Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
Interventions
Sofosbuvir, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
San Francisco, California • Indianapolis, Indiana • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1

NCT00735969
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Peginterferon, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever

NCT02116205
View directory record Official record
Conditions
Hemorrhagic Fever With Renal Syndrome
Interventions
HTNV/PUUV DNA vaccine, Placebo, TriGrid Delivery System (TDS)
Biological · Device
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 49 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Online HIV Prevention for Young Male Couples

NCT03284541
View directory record Official record
Conditions
Hiv, Chlamydia, Gonorrhea
Interventions
2GETHER, Existing Public Health Practice
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

NCT00708162
View directory record Official record
Conditions
HIV Infection
Interventions
Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
94
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 16, 2026, 5:22 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)

NCT06334341
View directory record Official record
Conditions
HIV Seropositivity
Interventions
Computer-based simulation training for providers, Best Practice Alert, HIV Risk Assessment, PrEP Informational Video
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1,380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 5:22 PM EDT
Not listed No phase listed Observational

Beat COVID-19 - Observational Trial

NCT04337762
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Beat COVID LLC
Industry
Eligibility
18 Years to 110 Years
Enrollment
100,000 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 4 Interventional Results available

Hepatitis C Virus(HCV) Heart and Lung Study

NCT02858180
View directory record Official record
Conditions
Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
Interventions
Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Detroit, Michigan • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)

NCT00110279
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2008 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Adherence Intervention for People With Low-literacy

NCT01061762
View directory record Official record
Conditions
HIV Infections
Interventions
Stick To It, Standard medication adherence counseling, Health Counseling
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 16, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Self-Managing HIV and Chronic Disease

NCT01032824
View directory record Official record
Conditions
HIV/AIDS
Interventions
Individual Telephone Counseling Intervention, Group Arm, Book Arm
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 16, 2026, 5:22 PM EDT
Completed No phase listed Observational

Alveolar Macrophage Proteomics in HIV-associated Emphysema

NCT00823927
View directory record Official record
Conditions
HIV, Emphysema, HIV Infections
Interventions
Not listed
Lead sponsor
Philip Diaz
Other
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of NVX-CoV2705

NCT07079670
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
NVX-CoV2705
Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 90 Years
Enrollment
676 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • Melrose Park, Illinois • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 16, 2026, 5:22 PM EDT
Not yet recruiting Not applicable Interventional

Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test

NCT07875270
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza B, RSV
Interventions
Flu A/B/COVID-19 + RSV Multiplex Rapid Test
Device
Lead sponsor
CorDx, Inc.
Industry
Eligibility
6 Months and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Alpharetta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

NCT04216589
View directory record Official record
Conditions
HIV Infections, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

NCT01353040
View directory record Official record
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-6003, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

No Excuses/Sin Buscar Excusas Intervention to Reduce Latino Men's HIV Risks

NCT00690690
View directory record Official record
Conditions
HIV Infections
Interventions
Video (group-delivered video-based intervention), HCT
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 49 Years · Male only
Enrollment
370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 16, 2026, 5:22 PM EDT
Not listed Not applicable Interventional

Adherence Intervention for HIV-infected Drug Users

NCT02907697
View directory record Official record
Conditions
HIV, Substance Use
Interventions
Life Steps-Drug Use, General Health Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 16, 2026, 5:22 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

NCT06008860
View directory record Official record
Conditions
COVID-19
Interventions
Experimental: Primary Cohort, Placebo Comparator: Primary Cohort - Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 16, 2026, 5:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

NCT04144348
View directory record Official record
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
mRNA-1653, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 16, 2026, 5:22 PM EDT
Withdrawn Phase 1 Interventional

CLBS119 for Repair of COVID-19 Induced Pulmonary Damage

NCT04522817
View directory record Official record
Conditions
Covid-19
Interventions
CLBS119
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 16, 2026, 5:22 PM EDT